Institutional investors hold a majority ownership of MYGN through the 149.76% of the outstanding shares that they control. This interest is also higher than at almost any other company in the Biotechnology industry. Last, during the quarter ended December 2013, these large investors purchased a net $3.9 million shares.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
BAILLIE GIFFORD & CO. Bought 4.1 Million shares of Myriad Genetics Inc